)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Omeros Corp (OMER) investor relations material
Omeros Corp Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Reported a Q3 2025 net loss of $30.9M ($0.47/share), with adjusted net loss at $22.1M ($0.34/share), and cash/investments of $36.1M as of September 30, 2025.
Entered a definitive asset purchase and license agreement with Novo Nordisk for zaltenibart, with $240M upfront and up to $2.1B in milestone and royalty payments, closing expected Q4 2025.
Resubmitted BLA for narsoplimab in TA-TMA to FDA; PDUFA date extended to December 26, 2025, with EMA review ongoing and opinion expected mid-2026.
Pipeline includes OMS1029 (long-acting MASP-2 antibody), OMS527 (PDE7 inhibitor for cocaine use disorder), and preclinical oncology and T-CAT programs.
U.S. commercial team is launch-ready for narsoplimab, with positive pre-approval engagement from stakeholders.
Financial highlights
Q3 2025 net loss: $30.9M ($0.47/share); nine-month net loss: $89.8M ($1.47/share), both improved year-over-year.
Adjusted net loss for Q3: $22.1M ($0.34/share); cash burn for Q3: $22M.
Cash and investments: $36.1M as of September 30, 2025.
Raised $20.3M via direct offering and $9M from ATM program in Q3; $15.3M raised YTD via ATM.
Operating expenses for Q3: $26.4M, down 25% year-over-year.
Outlook and guidance
Expect higher Q4 2025 operating expenses due to narsoplimab launch marketing; R&D expenses to remain steady.
Novo Nordisk upfront payment and cash on hand expected to cover debt repayment and fund operations for over 12 months.
FDA decision on narsoplimab BLA for TA-TMA expected by December 26, 2025; EMA opinion expected mid-2026.
Substantial doubt exists regarding ability to continue as a going concern without closing the Novo Nordisk transaction or raising additional capital.
Projected to be cash flow positive in 2027, contingent on Novo deal and narsoplimab approval.
Novo Nordisk deal: near-term milestone expectations?
Narsoplimab: How is exclusive reimbursement secured?
Pipeline programs: Which will be prioritized first?
Novo deal's impact on Omeros' debt profile
YARTEMLEA launch: Formulary approval strategy
Beyond YARTEMLEA, which programs are prioritized?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Omeros Corp earnings date
Q4 202531 Mar, 2026
Next Omeros Corp earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Omeros Corp is a biopharmaceutical company focused on developing and commercializing small-molecule and protein therapeutics. The company's research is centered on treatments for inflammation, immune disorders, and central nervous system conditions. Omeros also explores therapies targeting complement-mediated diseases, aiming to address various unmet medical needs. Its pipeline includes both clinical-stage and preclinical programs, with a focus on advancing innovative therapies that modulate key biological pathways involved in immune and inflammatory responses. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage